Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03887429 · ClinicalTrials.gov registry record · Phase 2
Restoring Cognitive Control (ReCon) in Acute Nicotine Withdrawal
A Phase 2 study, sponsored by Promentis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT03887429 is a Phase 2 study that has completed, run by Promentis Pharmaceuticals. The registered enrollment target is 34 participants.
The verdict
NCT03887429, a Phase 2 study, has completed, sponsored by Promentis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this study is to explore the safety, tolerability and activity of SXC-2023 or placebo when dosed for 5 days in adults with tobacco use disorder who voluntarily abstain from the use of cigarettes.
Interventions
- DRUG Placebos
- DRUG SXC-2023
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2019-03-04 |
| Est. Completion | 2019-07-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03887429
The ClinicalTrials.gov registry entry for NCT03887429 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Promentis Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT03887429 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03887429 about?
NCT03887429 is a clinical study titled "Restoring Cognitive Control (ReCon) in Acute Nicotine Withdrawal". The purpose of this study is to explore the safety, tolerability and activity of SXC-2023 or placebo when dosed for 5 days in adults with tobacco use disorder who voluntarily abstain from the use of cigarettes.
What is the current status of trial NCT03887429?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2019-03-04. Estimated completion is 2019-07-09.
What interventions are being tested in trial NCT03887429?
The interventions under investigation include: Placebos (DRUG), SXC-2023 (DRUG).
Who is sponsoring clinical trial NCT03887429?
This trial is sponsored by Promentis Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.